Nothing said here yet.
to join the conversation.
| TRAVERSA SERGIOChief Executive Officer | Buy | 100,000 | $410.0K | Thu, Sep 10 |
| Shenouda MagedChief Financial Officer | Buy | 79,800 | $339.1K | Thu, Sep 10 |
| Shenouda MagedChief Financial Officer | Buy | 120,200 | $504.8K | Wed, Sep 9 |
| TRAVERSA SERGIOChief Executive Officer | Buy | 100,000 | $418.0K | Wed, Sep 9 |
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc.
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Relmada Therapeutics (NASDAQ:RLMD) said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026.
Relmada Therapeutics Inc (RLMD) reports robust NDVO1 efficacy and a solid cash runway, but manufacturing delays push IND filing to end of 2026.
Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway.
Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation.
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc.